General Information of the Compound
| Compound ID |
CP0579302
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
Azeliragon
Show/Hide
|
||||||||||||||||||
| Synonyms |
Alzheimer's therapy (RAGE), Transtech/Pfizer
Alzheimer'streatment, TransTech/Pfizer
Alzheimers therapy, TransTech/Pfizer
Diabetic nephropathy therapy, Transtech/Pfizer
PF-04494700
PF-4494700
TTP-488
TTP-488)
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C32H38ClN3O2
|
||||||||||||||||||
| Molecular Weight |
532.128
|
||||||||||||||||||
| Canonical SMILES |
CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C32H38ClN3O2/c1-4-7-9-32-34-31(25-10-16-28(17-11-25)37-23-8-22-35(5-2)6-3)24-36(32)27-14-20-30(21-15-27)38-29-18-12-26(33)13-19-29/h10-21,24H,4-9,22-23H2,1-3H3
Show/Hide
|
||||||||||||||||||
| InChIKey |
KJNNWYBAOPXVJY-UHFFFAOYSA-N
|
||||||||||||||||||
| CAS |
603148-36-3
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT00897, Potassium voltage-gated channel subfamily H member 2
Protein ID: PT00871, Sodium-dependent serotonin transporter
Clinical Information about the Compound